BBus FCPA - Telix Pharmaceuticals Group Officer
| TLPPF Stock | USD 14.10 0.30 2.08% |
Insider
BBus FCPA is Group Officer of Telix Pharmaceuticals Limited
| Age | 57 |
| Phone | 61 3 3093 3897 |
| Web | https://telixpharma.com |
Telix Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of (0.4111) % which means that it has lost $0.4111 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (1.5507) %, meaning that it generated substantial loss on money invested by shareholders. Telix Pharmaceuticals' management efficiency ratios could be used to measure how well Telix Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Narinderjeet MS | Arcellx | 52 | |
| Hao Ede | Innovent Biologics | 64 | |
| Eduard MD | Innovent Biologics | N/A | |
| Annelise Vuidepot | Immunocore Holdings | N/A | |
| Sbastien Desprez | Immunocore Holdings | N/A | |
| Carrie MD | Zentalis Pharmaceuticals Llc | 54 | |
| Mihail MD | MAIA Biotechnology | 65 | |
| Martin MD | Ventyx Biosciences | 49 | |
| Jeff Fairman | Vaxcyte | 60 | |
| Christopher MSc | Keros Therapeutics | 50 | |
| David Tice | Arcellx | 53 | |
| Debra Nielsen | Immunocore Holdings | N/A | |
| Kimberly MD | Zentalis Pharmaceuticals Llc | 55 | |
| ACIS ACS | Genscript Biotech | 42 | |
| Neeraj Teotia | Arcellx | 49 | |
| Kevin Bunker | Zentalis Pharmaceuticals Llc | 52 | |
| Clayton Robertson | Immunocore Holdings | N/A | |
| Gwen Weld | Nautilus Biotechnology | 66 | |
| Michelle Gilson | Arcellx | 31 | |
| Anna Mowry | Nautilus Biotechnology | 40 | |
| Karen Alderete | Vaxcyte | N/A | |
Management Performance
| Return On Equity | -1.55 | |||
| Return On Asset | -0.41 |
Telix Pharmaceuticals Leadership Team
Elected by the shareholders, the Telix Pharmaceuticals' board of directors comprises two types of representatives: Telix Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Telix. The board's role is to monitor Telix Pharmaceuticals' management team and ensure that shareholders' interests are well served. Telix Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Telix Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Jyoti BappSc, Chief APAC | ||
| Meredith Crowe, Interim Culture | ||
| BSc BSc, Chief Scientist | ||
| Christian Davis, EMEA Marketing | ||
| Andreas MD, Chief Director | ||
| Amanda Griffin, Communications Mang | ||
| BEng DPhil, Group CoFounder | ||
| Kyahn Williamson, Sr Relations | ||
| BBus FCPA, Group Officer | ||
| Lena MoranAdams, G Counsel | ||
| AGIA ACG, Risk Governance |
Telix Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Telix Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.55 | |||
| Return On Asset | -0.41 | |||
| Operating Margin | (3.95) % | |||
| Current Valuation | 1.39 B | |||
| Shares Outstanding | 317.02 M | |||
| Shares Owned By Insiders | 27.60 % | |||
| Shares Owned By Institutions | 13.59 % | |||
| Price To Book | 21.16 X | |||
| Price To Sales | 52.21 X | |||
| Revenue | 4.9 M |
Currently Active Assets on Macroaxis
Additional Information and Resources on Investing in Telix Pink Sheet
When determining whether Telix Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Telix Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Telix Pharmaceuticals Limited Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Telix Pharmaceuticals Limited Stock:Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Telix Pharmaceuticals Limited. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey. You can also try the Sync Your Broker module to sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors..